Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22069400 | 0.87 | KMT2A (0.40) | KMT2AMEN1KDM4EMDM2ALDH1A1 | |
| SCHEMBL22069453 | 0.86 | NPSR1 (0.31) | KMT2AMEN1 | |
| SCHEMBL22069502 | 0.86 | KDM4E (0.31) | KMT2AMEN1KDM4EALDH1A1NAMPT | |
| SCHEMBL30741642 | 0.84 | HSD17B10 (0.36) | ALDH1A1TDP1POLB | |
| SCHEMBL22069348 | 0.84 | ALDH1A1 (0.35) | KMT2AMEN1ALDH1A1POLBSIGMAR1 | |
| SCHEMBL30741640 | 0.81 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL23656479 | 0.81 | KMT2A (0.37) | KMT2AMEN1KDM4EMDM2ALDH1A1 | |
| SCHEMBL22069494 | 0.80 | MCHR1 (0.40) | KMT2AMEN1KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL30741641 | 0.80 | ALDH1A1 (0.36) | KDM4EALDH1A1SIGMAR1 | |
| SCHEMBL20200022 | 0.80 | KMT2A (0.36) | KMT2AMEN1KDM4EMDM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814369-B2 | High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-11-14 | — | — | US | claimed |
| EP-3544964-B1 | HIGH RELAXIVITY GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | Bayer Pharma AG (DE) | 2020-06-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814369-B2 | High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging | RXFP1, RXFP2, RXFP3 | KMT2A 1995/4885MEN1 89/4885KDM4E 1649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.